Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • Studies of hydroxymethylglutaryl-CoA reductase inhibitors (statins) have reported some evidence of reductions in serum ALT[Gómez-Domínguez 2006; Hatzitolios 2004; Athyros 2006; Abel 2009]
  • The US National Lipid Association Statin Liver Safety Task Force has concluded that statin therapy is safe in patients with NAFLD and dyslipidemia[Bays 2014]
  • The AASLD and EASL guidelines recommend the use of statins for treatment of dyslipidemia in patients with NAFLD and NASH[AASLD NAFLD; EASL NAFLD]

Action required

Keywords: Diabetes, Hepatic Complications, Insulin Resistance, Special Populations

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.